- IXICO has been awarded four new contracts with leading pharmaceutical companies and a specialist biotechnology company, with a combined value of over GBP3.0m. The contracts are for global clinical trials of novel drugs for Alzheimer's disease which span the three major phases of drug development and are expected to run for the next two to four years, subject to the drugs successfully progressing through the clinical trials process.

They will utilise IXICO's expertise in the Alzheimer's field and our proprietary TrialTracker and Assessa digital platforms to collect imaging data and quantify changes in disease pathology in subjects enrolled in the study.

IXICO says the award of these contracts builds on its expertise in brain health following a long term contract for a Phase II/III global study in neurodegenerative disease and selection as the imaging analysis partner within The European Prevention of Alzheimer's Dementia Initiative (EPAD), announced in 2015.

Chief executive Professor Derek Hill said: "We are very pleased to have been awarded these significant projects. Not only do they validate the value our digital platforms provide, but also highlight the strength of IXICO's relationships with pharmaceutical and biotechnology companies developing drugs for Alzheimer's disease. The revenues from these contracts augment the board's confidence in meeting market expectations."

At 8:08am: [LON:IXI] IXICO plc share price was +1.5p at 31p

Story provided by